F
Fabio Efficace
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 250
Citations - 7555
Fabio Efficace is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Quality of life (healthcare) & Quality of life. The author has an hindex of 44, co-authored 222 publications receiving 6256 citations.
Papers
More filters
Journal ArticleDOI
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
TL;DR: Results indicated that PROs provide distinct prognostic information beyond standard clinical measures in cancer clinical trials and might be considered for stratification purposes in future trials, as they were often better predictors of survival than PS.
Journal ArticleDOI
An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer
George van Andel,Andrew Bottomley,Sophie D. Fosså,Fabio Efficace,Corneel Coens,Stephane Guerif,Howard Kynaston,Paolo Gontero,George N. Thalmann,Atif Akdas,Sven D’Haese,Neil K. Aaronson +11 more
TL;DR: The QLQ-PR25 demonstrates acceptable psychometric properties and clinical validity, and some caution should be used in interpreting the bowel function and side-effects of hormonal therapy scales; results can be reported at the individual item and scale level.
Journal ArticleDOI
Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials--Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?
Fabio Efficace,Andrew Bottomley,David Osoba,Carolyn C. Gotay,Henning Flechtner,Sven D’Haese,Alfredo Zurlo +6 more
TL;DR: It was found that HRQOL is a valuable source of information in RCTs of treatment in metastatic prostate cancer and a minimum set of criteria for assessing the reported outcomes in cancer clinical trials is necessary to make informed decisions in clinical practice.
Journal ArticleDOI
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace,Michele Baccarani,Massimo Breccia,Giuliana Alimena,Gianantonio Rosti,Francesco Cottone,Giorgio Lambertenghi Deliliers,Claudia Baratè,Antonella Russo Rossi,Giuseppe Fioritoni,Luigia Luciano,Diamante Turri,Bruno Martino,Francesco Di Raimondo,Melissa Dabusti,Micaela Bergamaschi,Pietro Leoni,Maria Pina Simula,Luciano Levato,Stefano Ulisciani,Dino Veneri,Simona Sica,Alessandro Rambaldi,Marco Vignetti,Franco Mandelli +24 more
TL;DR: The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.
Journal ArticleDOI
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)
Anne Brédart,Andrew Bottomley,Jane M Blazeby,Thierry Conroy,Corneel Coens,Sven D’Haese,Wei-Chu Chie,Eva Hammerlid,Juan Ignacio Arraras,Fabio Efficace,C. Rodary,S. Schraub,Massimo Costantini,Anna Costantini,F. Joly,Orhan Sezer,Darius Razavi,M. Mehlitz,M. Bielska-Lasota,Neil K. Aaronson +19 more
TL;DR: This study supports the acceptability to patients, and the psychometric robustness of the EORTC IN-PATSAT32 questionnaire, which was able to discriminate clearly between patients with differing care expectations and differing intentions to recommend their hospital to others.